Focal Therapy in Grade Group 3 Prostate Cancer.

IF 2.5 2区 医学 Q2 UROLOGY & NEPHROLOGY
Current Urology Reports Pub Date : 2024-11-01 Epub Date: 2024-07-02 DOI:10.1007/s11934-024-01211-x
Lee Pressler, Mariel Pressler
{"title":"Focal Therapy in Grade Group 3 Prostate Cancer.","authors":"Lee Pressler, Mariel Pressler","doi":"10.1007/s11934-024-01211-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of this review: </strong>Treatment of intermediate risk prostate cancer remains controversial. Clearly some patients with low volume favorable intermediate risk can be followed with active surveillance. Those with high volume bilateral disease need more radical whole gland therapy. The question remains on how to best treat low volume localized unfavorable intermediate risk prostate cancer (GG3) while maintaining quality of life. Focal therapy has been becoming a popular option for many patients with localized prostate cancer. Most studies looking at focal therapy for prostate cancer have been limited to GG1 and GG2, many of whom may not need treatment. We set out to review the literature evaluating the safety and efficacy of focal therapy for GG3 prostate cancer.</p><p><strong>Recent findings: </strong>We reviewed multiple peer review articles obtained from a PubMed search. While in field biopsy recurrence rates approach 20%, failure free survival and overall survival exceeds 90%. While focal therapy for unfavorable GG3 intermediate risk prostate cancer may have higher rates of local recurrence with appropriate post procedure follow up, patients who need salvage therapy are easily identified and survival rates are very high. Focal therapy is a good option for patients with localized low volume GG3 prostate cancer without compromising cancer survival and preserving quality of life.</p>","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":" ","pages":"271-275"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11366723/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Urology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11934-024-01211-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of this review: Treatment of intermediate risk prostate cancer remains controversial. Clearly some patients with low volume favorable intermediate risk can be followed with active surveillance. Those with high volume bilateral disease need more radical whole gland therapy. The question remains on how to best treat low volume localized unfavorable intermediate risk prostate cancer (GG3) while maintaining quality of life. Focal therapy has been becoming a popular option for many patients with localized prostate cancer. Most studies looking at focal therapy for prostate cancer have been limited to GG1 and GG2, many of whom may not need treatment. We set out to review the literature evaluating the safety and efficacy of focal therapy for GG3 prostate cancer.

Recent findings: We reviewed multiple peer review articles obtained from a PubMed search. While in field biopsy recurrence rates approach 20%, failure free survival and overall survival exceeds 90%. While focal therapy for unfavorable GG3 intermediate risk prostate cancer may have higher rates of local recurrence with appropriate post procedure follow up, patients who need salvage therapy are easily identified and survival rates are very high. Focal therapy is a good option for patients with localized low volume GG3 prostate cancer without compromising cancer survival and preserving quality of life.

3级前列腺癌的局部治疗
本综述的目的:中危前列腺癌的治疗仍存在争议。显然,一些体积较小的中危患者可以接受积极的监测。而那些双侧病变体积较大的患者则需要更彻底的全腺体治疗。问题仍然是如何在保持生活质量的同时,最好地治疗低体积局部不利的中危前列腺癌(GG3)。病灶治疗已成为许多局部前列腺癌患者的首选。大多数关于前列腺癌病灶治疗的研究仅限于 GG1 和 GG2,而其中许多患者可能并不需要治疗。我们着手回顾了评估GG3前列腺癌病灶治疗安全性和有效性的文献:我们查阅了从 PubMed 搜索获得的多篇同行评审文章。虽然现场活检复发率接近 20%,但无失败生存率和总生存率超过 90%。虽然针对不利的 GG3 中危前列腺癌的病灶治疗在适当的术后随访下可能会有较高的局部复发率,但需要挽救治疗的患者很容易被识别出来,而且生存率非常高。对于局部低体积 GG3 型前列腺癌患者来说,病灶治疗是一个不错的选择,既不会影响癌症生存,又能保证生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Urology Reports
Current Urology Reports UROLOGY & NEPHROLOGY-
CiteScore
4.60
自引率
3.80%
发文量
39
期刊介绍: This journal intends to review the most important, recently published findings in the field of urology. By providing clear, insightful, balanced contributions by international experts, the journal elucidates current and emerging approaches to the care and prevention of urologic diseases and conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as benign prostatic hyperplasia, erectile dysfunction, female urology, and kidney disease. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信